{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:50:51Z","timestamp":1787068251030,"version":"build-2736575974"},"reference-count":104,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,5,30]],"date-time":"2022-05-30T00:00:00Z","timestamp":1653868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,30]],"date-time":"2022-05-30T00:00:00Z","timestamp":1653868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Semin Immunopathol"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s00281-022-00941-9","type":"journal-article","created":{"date-parts":[[2022,5,30]],"date-time":"2022-05-30T07:03:48Z","timestamp":1653894228000},"page":"599-610","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Immuno-pathogenesis of neuromyelitis optica and emerging therapies"],"prefix":"10.1007","volume":"44","author":[{"given":"Norio","family":"Chihara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9048-0375","authenticated-orcid":false,"given":"Takashi","family":"Yamamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,30]]},"reference":[{"key":"941_CR1","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","volume":"364","author":"VA Lennon","year":"2004","unstructured":"Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, Nakashima I, Weinshenker BG (2004) A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364:2106\u20132112","journal-title":"Lancet"},{"key":"941_CR2","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1084\/jem.20050304","volume":"202","author":"VA Lennon","year":"2005","unstructured":"Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR (2005) IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 202:473\u2013477","journal-title":"J Exp Med"},{"key":"941_CR3","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","volume":"66","author":"DM Wingerchuk","year":"2006","unstructured":"Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG (2006) Revised diagnostic criteria for neuromyelitis optica. 2006. Neurology 66:1485\u20131489","journal-title":"Neurology"},{"key":"941_CR4","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, de Seze J, Fujihara K, Greenberg B, Jacob A, Jarius S, Lana-Peixoto M, Levy M, Simon JH, Tenembaum S, Traboulsee AL, Waters P, Wellik KE, Weinshenker BG, International Panel for NMOD (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85:177\u201389","journal-title":"Neurology"},{"key":"941_CR5","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/nrneurol.2013.118","volume":"9","author":"M Reindl","year":"2013","unstructured":"Reindl M, Di Pauli F, Rostasy K, Berger T (2013) The spectrum of MOG autoantibody-associated demyelinating diseases. Nat Rev Neurol 9:455\u2013461","journal-title":"Nat Rev Neurol"},{"key":"941_CR6","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jns.2006.10.008","volume":"252","author":"Y Warabi","year":"2007","unstructured":"Warabi Y, Matsumoto Y, Hayashi H (2007) Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination. J Neurol Sci 252:57\u201361","journal-title":"J Neurol Sci"},{"key":"941_CR7","doi-asserted-by":"publisher","first-page":"513","DOI":"10.5692\/clinicalneurol.53.513","volume":"53","author":"S Izaki","year":"2013","unstructured":"Izaki S, Narukawa S, Kubota A, Mitsui T, Fukaura H, Nomura K (2013) A case of neuromyelitis optica spectrum disorder developing a fulminant course with multiple white-matter lesions following fingolimod treatment. Rinsho Shinkeigaku 53:513\u2013517","journal-title":"Rinsho Shinkeigaku"},{"key":"941_CR8","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1212\/WNL.0b013e31826845fe","volume":"79","author":"A Jacob","year":"2012","unstructured":"Jacob A, Hutchinson M, Elsone L, Kelly S, Ali R, Saukans I, Tubridy N, Boggild M (2012) Does natalizumab therapy worsen neuromyelitis optica? Neurology 79:1065\u20131066","journal-title":"Neurology"},{"key":"941_CR9","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1056\/NEJMoa1900866","volume":"381","author":"SJ Pittock","year":"2019","unstructured":"Pittock SJ, Berthele A, Fujihara K, Kim HJ, Levy M, Palace J, Nakashima I, Terzi M, Totolyan N, Viswanathan S, Wang KC, Pace A, Fujita KP, Armstrong R, Wingerchuk DM (2019) Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N Engl J Med 381:614\u2013625","journal-title":"N Engl J Med"},{"key":"941_CR10","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","volume":"381","author":"T Yamamura","year":"2019","unstructured":"Yamamura T, Kleiter I, Fujihara K, Palace J, Greenberg B, Zakrzewska-Pniewska B, Patti F, Tsai CP, Saiz A, Yamazaki H, Kawata Y, Wright P, De Seze J (2019) Trial of satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med 381:2114\u20132124","journal-title":"N Engl J Med"},{"key":"941_CR11","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","volume":"19","author":"A Traboulsee","year":"2020","unstructured":"Traboulsee A, Greenberg BM, Bennett JL, Szczechowski L, Fox E, Shkrobot S, Yamamura T, Terada Y, Kawata Y, Wright P, Gianella-Borradori A, Garren H, Weinshenker BG (2020) Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol 19:402\u2013412","journal-title":"Lancet Neurol"},{"key":"941_CR12","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","volume":"394","author":"BAC Cree","year":"2019","unstructured":"Cree BAC, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, Fujihara K, Paul F, Cutter GR, Marignier R, Green AJ, Aktas O, Hartung HP, Lublin FD, Drappa J, Barron G, Madani S, Ratchford JN, She D, Cimbora D, Katz E, N-MOmentum study inverstigators (2019) Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial. Lancet 394:1352\u20131363","journal-title":"Lancet"},{"key":"941_CR13","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","volume":"19","author":"M Tahara","year":"2020","unstructured":"Tahara M, Oeda T, Okada K, Kiriyama T, Ochi K, Maruyama H, Fukaura H, Nomura K, Shimizu Y, Mori M, Nakashima I, Misu T, Umemura A, Yamamoto K, Sawada H (2020) Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 19:298\u2013306","journal-title":"Lancet Neurol"},{"key":"941_CR14","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1111\/j.1468-1331.2011.03529.x","volume":"19","author":"M Cossburn","year":"2012","unstructured":"Cossburn M, Tackley G, Baker K, Ingram G, Burtonwood M, Malik G, Pickersgill T, te Water Naude J, Robertson N (2012) The prevalence of neuromyelitis optica in South East Wales. Eur J Neurol 19:655\u20139","journal-title":"Eur J Neurol"},{"key":"941_CR15","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1212\/WNL.0b013e3182190f74","volume":"76","author":"N Asgari","year":"2011","unstructured":"Asgari N, Lillevang ST, Skejoe HP, Falah M, Stenager E, Kyvik KO (2011) A population-based study of neuromyelitis optica in Caucasians. Neurology 76:1589\u20131595","journal-title":"Neurology"},{"key":"941_CR16","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","volume":"6","author":"DM Wingerchuk","year":"2007","unstructured":"Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG (2007) The spectrum of neuromyelitis optica. Lancet Neurol 6:805\u2013815","journal-title":"Lancet Neurol"},{"key":"941_CR17","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1212\/WNL.0b013e3181ea9f15","volume":"75","author":"M Matiello","year":"2010","unstructured":"Matiello M, Kim HJ, Kim W, Brum DG, Barreira AA, Kingsbury DJ, Plant GT, Adoni T, Weinshenker BG (2010) Familial neuromyelitis optica. Neurology 75:310\u2013315","journal-title":"Neurology"},{"key":"941_CR18","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/jnnp-2012-302925","volume":"84","author":"S Yoshimura","year":"2013","unstructured":"Yoshimura S, Isobe N, Matsushita T, Yonekawa T, Masaki K, Sato S, Kawano Y, Kira J, South Japan Multiple Sclerosis Genetics C (2013) Distinct genetic and infectious profiles in Japanese neuromyelitis optica patients according to anti-aquaporin 4 antibody status. J Neurol Neurosurg Psychiatry 84:29\u201334","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"941_CR19","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1001\/archneurol.2007.17","volume":"65","author":"SJ Pittock","year":"2008","unstructured":"Pittock SJ, Lennon VA, de Seze J, Vermersch P, Homburger HA, Wingerchuk DM, Lucchinetti CF, Zephir H, Moder K, Weinshenker BG (2008) Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol 65:78\u201383","journal-title":"Arch Neurol"},{"key":"941_CR20","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","volume":"53","author":"DM Wingerchuk","year":"1999","unstructured":"Wingerchuk DM, Hogancamp WF, O\u2019Brien PC, Weinshenker BG (1999) The clinical course of neuromyelitis optica (Devic\u2019s syndrome). Neurology 53:1107\u20131114","journal-title":"Neurology"},{"key":"941_CR21","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00415-004-0271-0","volume":"251","author":"A Ghezzi","year":"2004","unstructured":"Ghezzi A, Bergamaschi R, Martinelli V, Trojano M, Tola MR, Merelli E, Mancardi L, Gallo P, Filippi M, Zaffaroni M, Comi G, Italian Devic\u2019s Study G (2004) Clinical characteristics, course and prognosis of relapsing Devic\u2019s neuromyelitis Optica. J Neurol 251:47\u201352","journal-title":"J Neurol"},{"key":"941_CR22","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.jaut.2009.09.013","volume":"34","author":"J Sellner","year":"2010","unstructured":"Sellner J, Hemmer B, Muhlau M (2010) The clinical spectrum and immunobiology of parainfectious neuromyelitis optica (Devic) syndromes. J Autoimmun 34:371\u2013379","journal-title":"J Autoimmun"},{"key":"941_CR23","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/nrn1252","volume":"4","author":"M Amiry-Moghaddam","year":"2003","unstructured":"Amiry-Moghaddam M, Ottersen OP (2003) The molecular basis of water transport in the brain. Nat Rev Neurosci 4:991\u20131001","journal-title":"Nat Rev Neurosci"},{"key":"941_CR24","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1177\/1352458513507822","volume":"20","author":"L Kremer","year":"2014","unstructured":"Kremer L, Mealy M, Jacob A, Nakashima I, Cabre P, Bigi S, Paul F, Jarius S, Aktas O, Elsone L, Mutch K, Levy M, Takai Y, Collongues N, Banwell B, Fujihara K, de Seze J (2014) Brainstem manifestations in neuromyelitis optica: a multicenter study of 258 patients. Mult Scler 20:843\u2013847","journal-title":"Mult Scler"},{"key":"941_CR25","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1001\/archneurol.2009.264","volume":"66","author":"T Kanbayashi","year":"2009","unstructured":"Kanbayashi T, Shimohata T, Nakashima I, Yaguchi H, Yabe I, Nishizawa M, Shimizu T, Nishino S (2009) Symptomatic narcolepsy in patients with neuromyelitis optica and multiple sclerosis: new neurochemical and immunological implications. Arch Neurol 66:1563\u20131566","journal-title":"Arch Neurol"},{"key":"941_CR26","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000110","volume":"2","author":"A Zekeridou","year":"2015","unstructured":"Zekeridou A, Lennon VA (2015) Aquaporin-4 autoimmunity. Neurol Neuroimmunol Neuroinflamm 2:e110","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"941_CR27","doi-asserted-by":"publisher","first-page":"e1642","DOI":"10.1212\/WNL.0000000000006392","volume":"91","author":"E Shosha","year":"2018","unstructured":"Shosha E, Dubey D, Palace J, Nakashima I, Jacob A, Fujihara K, Takahashi T, Whittam D, Leite MI, Misu T, Yoshiki T, Messina S, Elsone L, Majed M, Flanagan E, Gadoth A, Huebert C, Sagen J, Greenberg BM, Levy M, Banerjee A, Weinshenker B, Pittock SJ (2018) Area postrema syndrome: frequency, criteria, and severity in AQP4-IgG-positive NMOSD. Neurology 91:e1642\u2013e1651","journal-title":"Neurology"},{"key":"941_CR28","doi-asserted-by":"publisher","first-page":"20170690","DOI":"10.1259\/bjr.20170690","volume":"91","author":"KY Wang","year":"2018","unstructured":"Wang KY, Chetta J, Bains P, Balzer A, Lincoln J, Uribe T, Lincoln CM (2018) Spectrum of MRI brain lesion patterns in neuromyelitis optica spectrum disorder: a pictorial review. Br J Radiol 91:20170690","journal-title":"Br J Radiol"},{"key":"941_CR29","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1212\/WNL.0b013e318248dec1","volume":"78","author":"PJ Waters","year":"2012","unstructured":"Waters PJ, McKeon A, Leite MI, Rajasekharan S, Lennon VA, Villalobos A, Palace J, Mandrekar JN, Vincent A, Bar-Or A, Pittock SJ (2012) Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology 78:665\u201371","journal-title":"Neurology"},{"key":"941_CR30","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1093\/brain\/awm062","volume":"130","author":"T Takahashi","year":"2007","unstructured":"Takahashi T, Fujihara K, Nakashima I, Misu T, Miyazawa I, Nakamura M, Watanabe S, Shiga Y, Kanaoka C, Fujimori J, Sato S, Itoyama Y (2007) Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain 130:1235\u20131243","journal-title":"Brain"},{"key":"941_CR31","doi-asserted-by":"publisher","first-page":"3072","DOI":"10.1093\/brain\/awn240","volume":"131","author":"S Jarius","year":"2008","unstructured":"Jarius S, Aboul-Enein F, Waters P, Kuenz B, Hauser A, Berger T, Lang W, Reindl M, Vincent A, Kristoferitsch W (2008) Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain 131:3072\u20133080","journal-title":"Brain"},{"key":"941_CR32","doi-asserted-by":"crossref","unstructured":"kaishi T, Takahashi T, Nakashima I, Abe M, Ishii T, Aoki M, Fujihara K (2020) Repeated follow-up of AQP4-IgG titer by cell-based assay in neuromyelitis optica spectrum disorders (NMOSD). J Neurol Sci 410:116671","DOI":"10.1016\/j.jns.2020.116671"},{"key":"941_CR33","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1093\/brain\/awm047","volume":"130","author":"T Misu","year":"2007","unstructured":"Misu T, Fujihara K, Kakita A, Konno H, Nakamura M, Watanabe S, Takahashi T, Nakashima I, Takahashi H, Itoyama Y (2007) Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain 130:1224\u20131234","journal-title":"Brain"},{"key":"941_CR34","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1002\/ana.26067","volume":"89","author":"O Aktas","year":"2021","unstructured":"Aktas O, Smith MA, Rees WA, Bennett JL, She D, Katz E, Cree BAC, group NMs, the NMsi (2021) Serum glial fibrillary acidic protein: a neuromyelitis optica spectrum disorder biomarker. Ann Neurol 89:895\u2013910","journal-title":"Ann Neurol"},{"key":"941_CR35","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1136\/jnnp.2008.150698","volume":"80","author":"T Misu","year":"2009","unstructured":"Misu T, Takano R, Fujihara K, Takahashi T, Sato S, Itoyama Y (2009) Marked increase in cerebrospinal fluid glial fibrillar acidic protein in neuromyelitis optica: an astrocytic damage marker. J Neurol Neurosurg Psychiatry 80:575\u2013577","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"941_CR36","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1093\/brain\/awl371","volume":"130","author":"SF Roemer","year":"2007","unstructured":"Roemer SF, Parisi JE, Lennon VA, Benarroch EE, Lassmann H, Bruck W, Mandler RN, Weinshenker BG, Pittock SJ, Wingerchuk DM, Lucchinetti CF (2007) Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 130:1194\u20131205","journal-title":"Brain"},{"key":"941_CR37","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1177\/1352458513495581","volume":"20","author":"T Yonezu","year":"2014","unstructured":"Yonezu T, Ito S, Mori M, Ogawa Y, Makino T, Uzawa A, Kuwabara S (2014) \u201cBright spotty lesions\u201d on spinal magnetic resonance imaging differentiate neuromyelitis optica from multiple sclerosis. Mult Scler 20:331\u2013337","journal-title":"Mult Scler"},{"key":"941_CR38","doi-asserted-by":"crossref","unstructured":"Fujii C, Itoh K, Saito K, Satoh Y, Makino M, Nakagawa M, Yamaguchi K, Fushiki S, Mizuno T (2018) Persistent microscopic active inflammatory lesions in the central nervous system of a patient with neuromyelitis optica treated with oral prednisolone for more than 40years. eNeurological Sci 11:17-9","DOI":"10.1016\/j.ensci.2018.05.005"},{"key":"941_CR39","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/ana.21837","volume":"66","author":"M Bradl","year":"2009","unstructured":"Bradl M, Misu T, Takahashi T, Watanabe M, Mader S, Reindl M, Adzemovic M, Bauer J, Berger T, Fujihara K, Itoyama Y, Lassmann H (2009) Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol 66:630\u2013643","journal-title":"Ann Neurol"},{"key":"941_CR40","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.bbrc.2009.06.085","volume":"386","author":"M Kinoshita","year":"2009","unstructured":"Kinoshita M, Nakatsuji Y, Kimura T, Moriya M, Takata K, Okuno T, Kumanogoh A, Kajiyama K, Yoshikawa H, Sakoda S (2009) Neuromyelitis optica: passive transfer to rats by human immunoglobulin. Biochem Biophys Res Commun 386:623\u2013627","journal-title":"Biochem Biophys Res Commun"},{"key":"941_CR41","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1002\/ana.21802","volume":"66","author":"JL Bennett","year":"2009","unstructured":"Bennett JL, Lam C, Kalluri SR, Saikali P, Bautista K, Dupree C, Glogowska M, Case D, Antel JP, Owens GP, Gilden D, Nessler S, Stadelmann C, Hemmer B (2009) Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol 66:617\u2013629","journal-title":"Ann Neurol"},{"key":"941_CR42","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/brain\/awp309","volume":"133","author":"S Saadoun","year":"2010","unstructured":"Saadoun S, Waters P, Bell BA, Vincent A, Verkman AS, Papadopoulos MC (2010) Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain 133:349\u2013361","journal-title":"Brain"},{"key":"941_CR43","doi-asserted-by":"publisher","first-page":"13052","DOI":"10.1073\/pnas.91.26.13052","volume":"91","author":"JS Jung","year":"1994","unstructured":"Jung JS, Bhat RV, Preston GM, Guggino WB, Baraban JM, Agre P (1994) Molecular characterization of an aquaporin cDNA from brain: candidate osmoreceptor and regulator of water balance. Proc Natl Acad Sci U S A 91:13052\u201313056","journal-title":"Proc Natl Acad Sci U S A"},{"key":"941_CR44","doi-asserted-by":"publisher","first-page":"2936","DOI":"10.1016\/j.bpj.2011.05.012","volume":"100","author":"BJ Jin","year":"2011","unstructured":"Jin BJ, Rossi A, Verkman AS (2011) Model of aquaporin-4 supramolecular assembly in orthogonal arrays based on heterotetrameric association of M1\u2013M23 isoforms. Biophys J 100:2936\u20132945","journal-title":"Biophys J"},{"key":"941_CR45","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1111\/j.1471-4159.2008.05302.x","volume":"105","author":"GP Nicchia","year":"2008","unstructured":"Nicchia GP, Cogotzi L, Rossi A, Basco D, Brancaccio A, Svelto M, Frigeri A (2008) Expression of multiple AQP4 pools in the plasma membrane and their association with the dystrophin complex. J Neurochem 105:2156\u20132165","journal-title":"J Neurochem"},{"key":"941_CR46","doi-asserted-by":"publisher","first-page":"13609","DOI":"10.1073\/pnas.2235843100","volume":"100","author":"CS Furman","year":"2003","unstructured":"Furman CS, Gorelick-Feldman DA, Davidson KG, Yasumura T, Neely JD, Agre P, Rash JE (2003) Aquaporin-4 square array assembly: opposing actions of M1 and M23 isoforms. Proc Natl Acad Sci U S A 100:13609\u201313614","journal-title":"Proc Natl Acad Sci U S A"},{"key":"941_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.proghi.2004.03.001","volume":"39","author":"K Takata","year":"2004","unstructured":"Takata K, Matsuzaki T, Tajika Y (2004) Aquaporins: water channel proteins of the cell membrane. Prog Histochem Cytochem 39:1\u201383","journal-title":"Prog Histochem Cytochem"},{"key":"941_CR48","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/nri2620","volume":"9","author":"PF Zipfel","year":"2009","unstructured":"Zipfel PF, Skerka C (2009) Complement regulators and inhibitory proteins. Nat Rev Immunol 9:729\u2013740","journal-title":"Nat Rev Immunol"},{"key":"941_CR49","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s40478-017-0462-4","volume":"5","author":"X Yao","year":"2017","unstructured":"Yao X, Verkman AS (2017) Complement regulator CD59 prevents peripheral organ injury in rats made seropositive for neuromyelitis optica immunoglobulin G. Acta Neuropathol Commun 5:57","journal-title":"Acta Neuropathol Commun"},{"key":"941_CR50","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1172\/JCI122942","volume":"129","author":"J Soltys","year":"2019","unstructured":"Soltys J, Liu Y, Ritchie A, Wemlinger S, Schaller K, Schumann H, Owens GP, Bennett JL (2019) Membrane assembly of aquaporin-4 autoantibodies regulates classical complement activation in neuromyelitis optica. J Clin Invest 129:2000\u20132013","journal-title":"J Clin Invest"},{"key":"941_CR51","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000482","volume":"5","author":"A Sudo","year":"2018","unstructured":"Sudo A, Chihara N, Takenaka Y, Nakamura T, Ueda T, Sekiguchi K, Toda T (2018) Paraneoplastic NMOSD associated with EG junction adenocarcinoma expressing unprotected AQP4. Neurol Neuroimmunol Neuroinflamm 5:e482","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"941_CR52","doi-asserted-by":"crossref","unstructured":"Mitsui S, Tanaka Y, Kimura K, Jimbo N, Chihara N, Maniwa Y. 2021. Paraneoplastic neuromyelitis optica spectrum disorder associated with atypical thymic carcinoid: a case report. Ann Thorac Cardiovasc Surg","DOI":"10.5761\/atcs.cr.20-00354"},{"key":"941_CR53","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/ana.23651","volume":"72","author":"M Varrin-Doyer","year":"2012","unstructured":"Varrin-Doyer M, Spencer CM, Schulze-Topphoff U, Nelson PA, Stroud RM, Cree BA, Zamvil SS (2012) Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter. Ann Neurol 72:53\u201364","journal-title":"Ann Neurol"},{"key":"941_CR54","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1146\/annurev.immunol.021908.132710","volume":"27","author":"T Korn","year":"2009","unstructured":"Korn T, Bettelli E, Oukka M, Kuchroo VK (2009) IL-17 and Th17 Cells. Annu Rev Immunol 27:485\u2013517","journal-title":"Annu Rev Immunol"},{"key":"941_CR55","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/j.cell.2006.07.035","volume":"126","author":"II Ivanov","year":"2006","unstructured":"Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, Cua DJ, Littman DR (2006) The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 126:1121\u20131133","journal-title":"Cell"},{"key":"941_CR56","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000134","volume":"2","author":"E Melamed","year":"2015","unstructured":"Melamed E, Levy M, Waters PJ, Sato DK, Bennett JL, John GR, Hooper DC, Saiz A, Bar-Or A, Kim HJ, Pandit L, Leite MI, Asgari N, Kissani N, Hintzen R, Marignier R, Jarius S, Marcelletti J, Smith TJ, Yeaman MR, Han MH, Aktas O, Apiwattanakul M, Banwell B, Bichuetti D, Broadley S, Cabre P, Chitnis T, De Seze J, Fujihara K, Greenberg B, Hellwig K, Iorio R, Jarius S, Klawiter E, Kleiter I, Lana-Peixoto M, Nakashima OK, Palace J, Paul F, Prayoonwiwat N, Ruprecht K, Stuve O, Tedder T, Tenembaum S, Garrahan JP, Aires B, van Herle K, van Pelt D, Villoslada P, Waubant E, Weinshenker B, Wingerchuk D, Wurfel J, Zamvil S (2015) Update on biomarkers in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm 2:e134","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"941_CR57","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.immuni.2010.12.012","volume":"34","author":"R Morita","year":"2011","unstructured":"Morita R, Schmitt N, Bentebibel SE, Ranganathan R, Bourdery L, Zurawski G, Foucat E, Dullaers M, Oh S, Sabzghabaei N, Lavecchio EM, Punaro M, Pascual V, Banchereau J, Ueno H (2011) Human blood CXCR5(+)CD4(+) T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion. Immunity 34:108\u2013121","journal-title":"Immunity"},{"key":"941_CR58","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.3389\/fimmu.2019.02686","volume":"10","author":"P Nicolas","year":"2019","unstructured":"Nicolas P, Ruiz A, Cobo-Calvo A, Fiard G, Giraudon P, Vukusic S, Marignier R (2019) The balance in T follicular helper cell subsets is altered in neuromyelitis optica spectrum disorder patients and restored by rituximab. Front Immunol 10:2686","journal-title":"Front Immunol"},{"key":"941_CR59","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/324073a0","volume":"324","author":"T Hirano","year":"1986","unstructured":"Hirano T, Yasukawa K, Harada H, Taga T, Watanabe Y, Matsuda T, Kashiwamura S, Nakajima K, Koyama K, Iwamatsu A et al (1986) Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 324:73\u201376","journal-title":"Nature"},{"key":"941_CR60","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a016295","volume":"6","author":"T Tanaka","year":"2014","unstructured":"Tanaka T, Narazaki M, Kishimoto T (2014) IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol 6:a016295","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"941_CR61","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1177\/1352458510379247","volume":"16","author":"A Uzawa","year":"2010","unstructured":"Uzawa A, Mori M, Arai K, Sato Y, Hayakawa S, Masuda S, Taniguchi J, Kuwabara S (2010) Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6. Mult Scler 16:1443\u20131452","journal-title":"Mult Scler"},{"key":"941_CR62","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1111\/cei.12733","volume":"183","author":"PO Barros","year":"2016","unstructured":"Barros PO, Cassano T, Hygino J, Ferreira TB, Centuriao N, Kasahara TM, Andrade RM, Linhares UC, Andrade AF, Vasconcelos CC, Alvarenga R, Marignier R, Bento CA (2016) Prediction of disease severity in neuromyelitis optica by the levels of interleukin (IL)-6 produced during remission phase. Clin Exp Immunol 183:480\u2013489","journal-title":"Clin Exp Immunol"},{"key":"941_CR63","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1136\/jnnp.2011.241760","volume":"83","author":"A Uzawa","year":"2012","unstructured":"Uzawa A, Mori M, Sato Y, Masuda S, Kuwabara S (2012) CSF interleukin-6 level predicts recovery from neuromyelitis optica relapse. J Neurol Neurosurg Psychiatry 83:339\u2013340","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"941_CR64","doi-asserted-by":"crossref","unstructured":"Fujihara K, Bennett JL, de Seze J, Haramura M, Kleiter I, Weinshenker BG, Kang D, Mughal T, Yamamura T. 2020. Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology. Neurol Neuroimmunol Neuroinflamm 7","DOI":"10.1212\/NXI.0000000000000841"},{"key":"941_CR65","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nature04753","volume":"441","author":"E Bettelli","year":"2006","unstructured":"Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK (2006) Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441:235\u2013238","journal-title":"Nature"},{"key":"941_CR66","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/nature05970","volume":"448","author":"T Korn","year":"2007","unstructured":"Korn T, Bettelli E, Gao W, Awasthi A, Jager A, Strom TB, Oukka M, Kuchroo VK (2007) IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 448:484\u2013487","journal-title":"Nature"},{"key":"941_CR67","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/icb.2012.17","volume":"90","author":"SA Diehl","year":"2012","unstructured":"Diehl SA, Schmidlin H, Nagasawa M, Blom B, Spits H (2012) IL-6 triggers IL-21 production by human CD4+ T cells to drive STAT3-dependent plasma cell differentiation in B cells. Immunol Cell Biol 90:802\u2013811","journal-title":"Immunol Cell Biol"},{"key":"941_CR68","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1084\/jem.20130699","volume":"210","author":"N Molnarfi","year":"2013","unstructured":"Molnarfi N, Schulze-Topphoff U, Weber MS, Patarroyo JC, Prod\u2019homme T, Varrin-Doyer M, Shetty A, Linington C, Slavin AJ, Hidalgo J, Jenne DE, Wekerle H, Sobel RA, Bernard CC, Shlomchik MJ, Zamvil SS (2013) MHC class II-dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies. J Exp Med 210:2921\u201337","journal-title":"J Exp Med"},{"key":"941_CR69","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/nri1886","volume":"6","author":"A Radbruch","year":"2006","unstructured":"Radbruch A, Muehlinghaus G, Luger EO, Inamine A, Smith KG, Dorner T, Hiepe F (2006) Competence and competition: the challenge of becoming a long-lived plasma cell. Nat Rev Immunol 6:741\u2013750","journal-title":"Nat Rev Immunol"},{"key":"941_CR70","doi-asserted-by":"publisher","first-page":"3701","DOI":"10.1073\/pnas.1017385108","volume":"108","author":"N Chihara","year":"2011","unstructured":"Chihara N, Aranami T, Sato W, Miyazaki Y, Miyake S, Okamoto T, Ogawa M, Toda T, Yamamura T (2011) Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci U S A 108:3701\u20133706","journal-title":"Proc Natl Acad Sci U S A"},{"key":"941_CR71","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1002\/acn3.418","volume":"4","author":"MC Kowarik","year":"2017","unstructured":"Kowarik MC, Astling D, Gasperi C, Wemlinger S, Schumann H, Dzieciatkowska M, Ritchie AM, Hemmer B, Owens GP, Bennett JL (2017) CNS aquaporin-4-specific B cells connect with multiple B-cell compartments in neuromyelitis optica spectrum disorder. Ann Clin Transl Neurol 4:369\u2013380","journal-title":"Ann Clin Transl Neurol"},{"key":"941_CR72","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0061835","volume":"8","author":"T Matsushita","year":"2013","unstructured":"Matsushita T, Tateishi T, Isobe N, Yonekawa T, Yamasaki R, Matsuse D, Murai H, Kira J (2013) Characteristic cerebrospinal fluid cytokine\/chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis. PLoS ONE 8:e61835","journal-title":"PLoS ONE"},{"key":"941_CR73","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0083036","volume":"8","author":"N Chihara","year":"2013","unstructured":"Chihara N, Aranami T, Oki S, Matsuoka T, Nakamura M, Kishida H, Yokoyama K, Kuroiwa Y, Hattori N, Okamoto T, Murata M, Toda T, Miyake S, Yamamura T (2013) Plasmablasts as migratory IgG-producing cells in the pathogenesis of neuromyelitis optica. PLoS ONE 8:e83036","journal-title":"PLoS ONE"},{"key":"941_CR74","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1172\/JCI78084","volume":"125","author":"J Suurmond","year":"2015","unstructured":"Suurmond J, Diamond B (2015) Autoantibodies in systemic autoimmune diseases: specificity and pathogenicity. J Clin Invest 125:2194\u20132202","journal-title":"J Clin Invest"},{"key":"941_CR75","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1093\/brain\/awz106","volume":"142","author":"E Cotzomi","year":"2019","unstructured":"Cotzomi E, Stathopoulos P, Lee CS, Ritchie AM, Soltys JN, Delmotte FR, Oe T, Sng J, Jiang R, Ma AK, Vander Heiden JA, Kleinstein SH, Levy M, Bennett JL, Meffre E, O\u2019Connor KC (2019) Early B cell tolerance defects in neuromyelitis optica favour anti-AQP4 autoantibody production. Brain 142:1598\u20131615","journal-title":"Brain"},{"issue":"725\u201339","key":"941_CR76","volume":"49","author":"SA Jenks","year":"2018","unstructured":"Jenks SA, Cashman KS, Zumaquero E, Marigorta UM, Patel AV, Wang X, Tomar D, Woodruff MC, Simon Z, Bugrovsky R, Blalock EL, Scharer CD, Tipton CM, Wei C, Lim SS, Petri M, Niewold TB, Anolik JH, Gibson G, Lee FE, Boss JM, Lund FE, Sanz I (2018) Distinct effector B cells induced by unregulated toll-like receptor 7 contribute to pathogenic responses in systemic lupus erythematosus. Immunity 49(725\u201339):e6","journal-title":"Immunity"},{"key":"941_CR77","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.606338","volume":"11","author":"C Ruschil","year":"2020","unstructured":"Ruschil C, Gabernet G, Lepennetier G, Heumos S, Kaminski M, Hracsko Z, Irmler M, Beckers J, Ziemann U, Nahnsen S, Owens GP, Bennett JL, Hemmer B, Kowarik MC (2020) Specific induction of double negative B cells during protective and pathogenic immune responses. Front Immunol 11:606338","journal-title":"Front Immunol"},{"key":"941_CR78","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1093\/brain\/awy010","volume":"141","author":"R Wilson","year":"2018","unstructured":"Wilson R, Makuch M, Kienzler AK, Varley J, Taylor J, Woodhall M, Palace J, Leite MI, Waters P, Irani SR (2018) Condition-dependent generation of aquaporin-4 antibodies from circulating B cells in neuromyelitis optica. Brain 141:1063\u20131074","journal-title":"Brain"},{"key":"941_CR79","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000311","volume":"4","author":"Y Takeshita","year":"2017","unstructured":"Takeshita Y, Obermeier B, Cotleur AC, Spampinato SF, Shimizu F, Yamamoto E, Sano Y, Kryzer TJ, Lennon VA, Kanda T, Ransohoff RM (2017) Effects of neuromyelitis optica-IgG at the blood-brain barrier in vitro. Neurol Neuroimmunol Neuroinflamm 4:e311","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"941_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2020.577211","volume":"342","author":"F Petkovic","year":"2020","unstructured":"Petkovic F, Lazzarino GP, Engblom D, Blomqvist A (2020) IL-6R expressed on CNS vascular endothelial cells contributes to the development of experimental autoimmune encephalomyelitis in mice. J Neuroimmunol 342:577211","journal-title":"J Neuroimmunol"},{"key":"941_CR81","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1084\/jem.20081241","volume":"205","author":"SR Hinson","year":"2008","unstructured":"Hinson SR, Roemer SF, Lucchinetti CF, Fryer JP, Kryzer TJ, Chamberlain JL, Howe CL, Pittock SJ, Lennon VA (2008) Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2. J Exp Med 205:2473\u20132481","journal-title":"J Exp Med"},{"key":"941_CR82","first-page":"4025","volume":"130","author":"T Chen","year":"2020","unstructured":"Chen T, Lennon VA, Liu YU, Bosco DB, Li Y, Yi MH, Zhu J, Wei S, Wu LJ (2020) Astrocyte-microglia interaction drives evolving neuromyelitis optica lesion. J Clin Invest 130:4025\u20134038","journal-title":"J Clin Invest"},{"key":"941_CR83","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1212\/WNL.51.4.1219","volume":"51","author":"RN Mandler","year":"1998","unstructured":"Mandler RN, Ahmed W, Dencoff JE (1998) Devic\u2019s neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology 51:1219\u20131220","journal-title":"Neurology"},{"key":"941_CR84","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1001\/archneurol.2009.175","volume":"66","author":"A Jacob","year":"2009","unstructured":"Jacob A, Matiello M, Weinshenker BG, Wingerchuk DM, Lucchinetti C, Shuster E, Carter J, Keegan BM, Kantarci OH, Pittock SJ (2009) Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol 66:1128\u20131133","journal-title":"Arch Neurol"},{"key":"941_CR85","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1136\/jnnp-2012-304774","volume":"84","author":"J Kitley","year":"2013","unstructured":"Kitley J, Elsone L, George J, Waters P, Woodhall M, Vincent A, Jacob A, Leite MI, Palace J (2013) Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies. J Neurol Neurosurg Psychiatry 84:918\u2013921","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"941_CR86","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1177\/1352458514546793","volume":"21","author":"M Tanaka","year":"2015","unstructured":"Tanaka M, Kinoshita M, Tanaka K (2015) Corticosteroid and tacrolimus treatment in neuromyelitis optica related disorders. Mult Scler 21:669","journal-title":"Mult Scler"},{"key":"941_CR87","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s00415-012-6692-2","volume":"260","author":"T Kageyama","year":"2013","unstructured":"Kageyama T, Komori M, Miyamoto K, Ozaki A, Suenaga T, Takahashi R, Kusunoki S, Matsumoto S, Kondo T (2013) Combination of cyclosporine A with corticosteroids is effective for the treatment of neuromyelitis optica. J Neurol 260:627\u2013634","journal-title":"J Neurol"},{"key":"941_CR88","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1001\/jamaneurol.2016.1637","volume":"73","author":"V Damato","year":"2016","unstructured":"Damato V, Evoli A, Iorio R (2016) Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis. JAMA Neurol 73:1342\u20131348","journal-title":"JAMA Neurol"},{"key":"941_CR89","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/S0161-5890(96)00078-8","volume":"33","author":"TC Thomas","year":"1996","unstructured":"Thomas TC, Rollins SA, Rother RP, Giannoni MA, Hartman SL, Elliott EA, Nye SH, Matis LA, Squinto SP, Evans MJ (1996) Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol Immunol 33:1389\u20131401","journal-title":"Mol Immunol"},{"key":"941_CR90","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1073\/pnas.1109980108","volume":"109","author":"SR Hinson","year":"2012","unstructured":"Hinson SR, Romero MF, Popescu BF, Lucchinetti CF, Fryer JP, Wolburg H, Fallier-Becker P, Noell S, Lennon VA (2012) Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes. Proc Natl Acad Sci U S A 109:1245\u20131250","journal-title":"Proc Natl Acad Sci U S A"},{"key":"941_CR91","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1186\/s12974-018-1333-z","volume":"15","author":"T Duan","year":"2018","unstructured":"Duan T, Smith AJ, Verkman AS (2018) Complement-dependent bystander injury to neurons in AQP4-IgG seropositive neuromyelitis optica. J Neuroinflammation 15:294","journal-title":"J Neuroinflammation"},{"key":"941_CR92","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s41232-016-0013-6","volume":"36","author":"T Horiuchi","year":"2016","unstructured":"Horiuchi T, Tsukamoto H (2016) Complement-targeted therapy: development of C5- and C5a-targeted inhibition. Inflamm Regen 36:11","journal-title":"Inflamm Regen"},{"key":"941_CR93","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.3389\/fimmu.2018.01694","volume":"9","author":"P Piatek","year":"2018","unstructured":"Piatek P, Domowicz M, Lewkowicz N, Przygodzka P, Matysiak M, Dzitko K, Lewkowicz P (2018) C5a-preactivated neutrophils are critical for autoimmune-induced astrocyte dysregulation in neuromyelitis optica spectrum disorder. Front Immunol 9:1694","journal-title":"Front Immunol"},{"key":"941_CR94","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/S1474-4422(13)70076-0","volume":"12","author":"SJ Pittock","year":"2013","unstructured":"Pittock SJ, Lennon VA, McKeon A, Mandrekar J, Weinshenker BG, Lucchinetti CF, O\u2019Toole O, Wingerchuk DM (2013) Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol 12:554\u2013562","journal-title":"Lancet Neurol"},{"key":"941_CR95","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1002\/ana.26049","volume":"89","author":"DM Wingerchuk","year":"2021","unstructured":"Wingerchuk DM, Fujihara K, Palace J, Berthele A, Levy M, Kim HJ, Nakashima I, Oreja-Guevara C, Wang KC, Miller L, Shang S, Sabatella G, Yountz M, Pittock SJ, Group PS (2021) Long-term safety and efficacy of eculizumab in aquaporin-4 IgG-positive NMOSD. Ann Neurol 89:1088\u201398","journal-title":"Ann Neurol"},{"key":"941_CR96","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1038\/nbt.1691","volume":"28","author":"T Igawa","year":"2010","unstructured":"Igawa T, Ishii S, Tachibana T, Maeda A, Higuchi Y, Shimaoka S, Moriyama C, Watanabe T, Takubo R, Doi Y, Wakabayashi T, Hayasaka A, Kadono S, Miyazaki T, Haraya K, Sekimori Y, Kojima T, Nabuchi Y, Aso Y, Kawabe Y, Hattori K (2010) Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization. Nat Biotechnol 28:1203\u20137","journal-title":"Nat Biotechnol"},{"key":"941_CR97","doi-asserted-by":"publisher","first-page":"827","DOI":"10.3109\/s10165-012-0715-9","volume":"23","author":"M Araki","year":"2013","unstructured":"Araki M, Aranami T, Matsuoka T, Nakamura M, Miyake S, Yamamura T (2013) Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab. Mod Rheumatol 23:827\u2013831","journal-title":"Mod Rheumatol"},{"key":"941_CR98","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1001\/jamaneurol.2013.1246","volume":"70","author":"I Ayzenberg","year":"2013","unstructured":"Ayzenberg I, Kleiter I, Schroder A, Hellwig K, Chan A, Yamamura T, Gold R (2013) Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy. JAMA Neurol 70:394\u2013397","journal-title":"JAMA Neurol"},{"key":"941_CR99","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1212\/WNL.0000000000000317","volume":"82","author":"M Araki","year":"2014","unstructured":"Araki M, Matsuoka T, Miyamoto K, Kusunoki S, Okamoto T, Murata M, Miyake S, Aranami T, Yamamura T (2014) Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study. Neurology 82:1302\u20131306","journal-title":"Neurology"},{"key":"941_CR100","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S1474-4422(20)30070-3","volume":"19","author":"C Zhang","year":"2020","unstructured":"Zhang C, Zhang M, Qiu W, Ma H, Zhang X, Zhu Z, Yang CS, Jia D, Zhang TX, Yuan M, Feng Y, Yang L, Lu W, Yu C, Bennett JL, Shi FD, Investigators TS (2020) Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial. Lancet Neurol 19:391\u2013401","journal-title":"Lancet Neurol"},{"key":"941_CR101","doi-asserted-by":"publisher","first-page":"580","DOI":"10.4049\/jimmunol.1400118","volume":"193","author":"A Palanichamy","year":"2014","unstructured":"Palanichamy A, Jahn S, Nickles D, Derstine M, Abounasr A, Hauser SL, Baranzini SE, Leppert D, von Budingen HC (2014) Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients. J Immunol 193:580\u2013586","journal-title":"J Immunol"},{"key":"941_CR102","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/nrneurol.2012.203","volume":"8","author":"M Krumbholz","year":"2012","unstructured":"Krumbholz M, Derfuss T, Hohlfeld R, Meinl E (2012) B cells and antibodies in multiple sclerosis pathogenesis and therapy. Nat Rev Neurol 8:613\u2013623","journal-title":"Nat Rev Neurol"},{"key":"941_CR103","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1093\/annonc\/mdq583","volume":"22","author":"AM Evens","year":"2011","unstructured":"Evens AM, Jovanovic BD, Su YC, Raisch DW, Ganger D, Belknap SM, Dai MS, Chiu BC, Fintel B, Cheng Y, Chuang SS, Lee MY, Chen TY, Lin SF, Kuo CY (2011) Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol 22:1170\u20131180","journal-title":"Ann Oncol"},{"key":"941_CR104","doi-asserted-by":"crossref","unstructured":"Rensel M, Zabeti A, Mealy MA, Cimbora D, She D, Drappa J, Katz E. 2021. Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: analysis of aquaporin-4-immunoglobulin G-seropositive participants taking inebilizumab for 4 years in the N-MOmentum trial. Mult Scler: 13524585211047223","DOI":"10.1177\/13524585211047223"}],"container-title":["Seminars in Immunopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00281-022-00941-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00281-022-00941-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00281-022-00941-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T13:41:30Z","timestamp":1664372490000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00281-022-00941-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,30]]},"references-count":104,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["941"],"URL":"https:\/\/doi.org\/10.1007\/s00281-022-00941-9","relation":{},"ISSN":["1863-2297","1863-2300"],"issn-type":[{"value":"1863-2297","type":"print"},{"value":"1863-2300","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,30]]},"assertion":[{"value":"7 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that this review article does not contain conduction of any animal experiments or studies involving human participants. The authors wrote the article based on the published information without violating any ethical issues.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}},{"value":"N.C. received speakers\u2019 honorarium from Alexion Pharmaceuticals, Inc., Chugai Pharmaceutical Co., Ltd., and Mitsubishi Tanabe Pharma Corporation. T.Y. received speakers\u2019 honorarium from Alexion Pharmaceuticals, Inc., Chugai Pharmaceutical Co., Ltd., Roche, and Mitsubishi Tanabe Pharma Corporation. T.Y. served as scientific advisor for Chugai and Roche.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}